Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hyperpolarized C-13 Pyruvate as a Biomarker of PI3K/mTOR Pathway Inhibition in Patients With Advanced Solid Tumor Malignancies

NCT02913131 is registered in ClinicalTrials.gov with Rahul Aggarwal as lead sponsor.

NCT NCT02913131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02913131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hyperpolarized C-13 Pyruvate as a Biomarker of PI3K/mTOR Pathway Inhibition in Patients With Advanced Solid Tumor Malignancies
Lead sponsor
Rahul Aggarwal
Phase
Phase 1/2
Overall status
Terminated
Start date
October 20, 2016
Completion date
April 5, 2021
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer